Stable β-Carboline Polymorph for Consistent Drug Formulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing technologies do not provide a stable crystalline polymorphic form of 6-fluoro-9-methyl-β-carboline suitable for pharmaceutical formulations, leading to inconsistencies in drug performance and potential toxicity due to polymorph instability.

Innovation Solution

Identification and stabilization of a specific polymorphic form (polymorph B) of 6-fluoro-9-methyl-β-carboline, characterized by unique X-ray diffraction, NMR, and IR spectra, which is stable under normal storage and formulation conditions, allowing its use in pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If recrystallization from solution is performed to obtain crystalline polymorphic form, then crystal structure and purity are improved, but polymorph stability deteriorates leading to inconsistent drug performance

Engineering Contradiction:

Improvecrystal structure controlVSAvoidpolymorph stability

Core Design Contradiction:

Manufacturing precisionVSReliability

Solution Approach 1:

The patent applies parameter changes by systematically varying crystallization conditions including solvent selection, temperature profiles, pH values, and presence of additives to transform the unstable polymorph into a stable crystalline form with consistent properties

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces conventional mechanical mixing and filtration methods with controlled crystallization processes that utilize solubility equilibria, nucleation theory, and phase transition mechanisms to achieve stable polymorphic forms

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If multiple crystalline polymorphic forms are produced, then manufacturing flexibility is improved, but product consistency and bioavailability deteriorate

Engineering Contradiction:

Improvecrystallization method optionsVSAvoidpolymorph consistency

Core Design Contradiction:

Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent implements feedback mechanisms through in-process monitoring of crystal formation, using techniques such as polarized light microscopy, HPLC, and X-ray diffraction to detect polymorphic form and adjust crystallization parameters in real-time to ensure consistent product quality

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent applies preliminary action by pre-establishing optimized crystallization protocols, selecting appropriate solvents and conditions before production begins, and preparing seed crystals or template structures to ensure consistent polymorphic form from batch to batch

Inventive Principle:

Principle #10Preliminary action

3Productivity

If unstable polymorphic forms are used in pharmaceutical formulations, then formulation development is accelerated, but therapeutic efficacy and safety deteriorate due to toxicity

Engineering Contradiction:

Improveformulation development speedVSAvoidtoxicity and bioavailability inconsistency

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes temporary or disposable crystallization additives, solvents, and process aids that can be easily removed or degraded, allowing rapid formulation development without long-term stability issues from persistent unstable polymorphic forms

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent converts the potential harm of polymorphic instability into a benefit by utilizing controlled phase transitions and polymorphic transformations to achieve a stable crystalline form that provides both rapid dissolution and consistent therapeutic efficacy, turning potential toxicity into therapeutic advantage

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Polymorph B ensures consistent bioavailability and stability of drug substances in formulations, enhancing therapeutic efficacy in treating hearing damage and vestibular disorders, with improved recovery from noise-induced hearing loss.

Implementation Method 1

characterized by unique X-ray diffraction, NMR, and IR spectra

Methodology Applied

Scientific EffectX-ray diffraction: X-Ray

Implementation Method 2

characterized by unique X-ray diffraction, NMR, and IR spectra

Methodology Applied

Scientific EffectNMR spectroscopy:

Implementation Method 3

characterized by unique X-ray diffraction, NMR, and IR spectra

Methodology Applied

Scientific EffectIR spectroscopy: Absorption Spectroscopy

Data Source

PatentUS12466824B2Stable polymorphic form of 6-fluoro-9-methyl-9H-β-carboline and uses thereof

Publication Date: 2025.11.11 AUDIOCURE PHARMA GMBH

AI summary

The present invention relates to a stable crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline of formula (I) a method for preparation of said crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline, and a pharmaceutical composition comprising said crystalline polymorphic form of 6-fluoro-9-methyl-9H-β-carboline. Furthermore, the present invention relates to the use of said stable crystalline polymorphic form and the use of the pharmaceutical composition comprising said stable crystalline polymorphic form in the treatment and/or prophylaxis of hearing damage, vertigo or vestibular disorders.